Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres.
about
Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurementsCytoplasmic p21WAF1/CIP1 expression is correlated with HER-2/ neu in breast cancer and is an independent predictor of prognosisReal-time PCR complements immunohistochemistry in the determination of HER-2/neu status in breast cancerNanotheranostics for personalized medicineHER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneityBreastfeeding in relation to risk of different breast cancer characteristics.A simple and reliable pretreatment protocol facilitates fluorescent in situ hybridisation on tissue microarrays of paraffin wax embedded tumour samples.Low Level of Her-2 Locus Amplification by Fluorescent In Situ Hybridization Does Not Correlate with Her-2 Protein Overexpression by Immunohistochemistry in Barrett's Esophagus.Chromosome 17 polysomy: correlation with histological parameters and HER2NEU gene amplification.The epidermal growth factor receptor family in breast cancer.Testing for HER2 in Breast Cancer: A Continuing Evolution.High-density SNP arrays improve detection of HER2 amplification and polyploidy in breast tumorsHER2 in solid tumors: more than 10 years under the microscope; where are we now?IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest in breast carcinoma.Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.Overexpression of cyclo-oxygenase-2 is an independent predictor of unfavourable outcome in node-negative breast cancer, but is not associated with protein kinase B (Akt) and mitogen-activated protein kinase (ERK1/2, p38) activation or with Her-2/neuTesting for HER2-positive breast cancer: a systematic review and cost-effectiveness analysisReal-time quantitative PCR of microdissected paraffin-embedded breast carcinoma: an alternative method for HER-2/neu analysis.Testing for HER2 in breast cancer.Therapeutic antibodies against cancer.Amplification of the HER2 gene in breast cancers testing 2+ weak positive by HercepTest immunohistochemistry: false-positive or false-negative immunohistochemistry?External quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme.Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays.Relative Prognostic Value of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Operable Oesophagogastric Cancer.Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approachImmunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in invasive breast cancer in women.Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patientsHigh prevalence of HER-2/neu overexpression in female breast cancer among an Iraqi population exposed to depleted uranium.Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial.Triple-negative breast cancers are increased in black women regardless of age or body mass indexPersonalizing therapies for gastric cancer: molecular mechanisms and novel targeted therapiesReduction in HER-2 protein expression in a breast tumor HER-2 positive after only one injection of Trastuzumab: a case report.Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer.Impact of HER2 copy number in IHC2+/FISH-amplified breast cancer on outcome of adjuvant trastuzumab treatment in a large UK cancer network.Clinical and health economic outcomes of alternative HER2 test strategies for guiding adjuvant trastuzumab therapy.HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis.Evaluation of HER2 in breast cancer: reality and expectations.Imaging EGFR and HER2 by PET and SPECT: a review.Systemic treatment of HER2+ metastatic breast cancer: clinical conundrums and future perspectives.HER2 assessment by silver in situ hybridization: where are we now?
P2860
Q24673038-D73E994A-7F0D-4F7D-B370-71A25DF9B50DQ24802985-CBE54214-1008-4887-AFCD-324808CFEE73Q25257296-7B0745C4-312F-490E-9259-18E5966097DDQ26851449-B4D2E53B-E325-40D5-B507-306001325A66Q27006811-5D424C69-6B1E-42F3-87CF-716E6EB1D7DAQ33617363-C0C633E3-1D66-4C31-BDB9-FAAB93013C2AQ33919227-9CEB48D9-45EF-4EF3-ACB7-EA63C92D131FQ33984756-F3A64573-8487-41BE-8FE7-07ED70B71947Q34361300-15E023F9-8CBB-4F92-8A3F-DA733C39159CQ34363400-F8A5647A-BE19-424D-90BE-3BD6214B1E3DQ34424285-6348056C-D7C2-41FE-AE2B-92B326C199A6Q35078859-F964BB81-36C8-4996-B244-54E207FDA51EQ35211263-38B9C05B-1A55-4752-B86C-A03A2C23DD67Q35588768-7D777AEC-1140-4E1C-8D8F-18BFDCD26E17Q35634450-F0A94FB4-25E3-4DBC-AA05-0E0FFE1CBED1Q35770111-6857094B-D7E2-4DAD-AF78-43D8ADE070BDQ35778406-074D3CFD-3170-43D5-A571-D6537465F239Q35789663-D77EC61A-1017-4D34-8778-93E1BA7F94BAQ35871999-0C991674-1CFC-4A44-97D8-8BAD7CC88902Q35908498-9F7E7C26-A069-42F8-9E25-A9D9FE53A44EQ35954388-35FAC528-19F8-47F0-A2B8-DEB85E4E3543Q36017256-8F2AAA7A-848E-4F04-B404-10BBF67CA29CQ36026180-374779B3-9998-41BA-BAF2-69168608D445Q36140927-A094DA6C-BD3F-4F85-B183-61F06D5EC1FFQ36245435-82186D84-C02B-4AFA-9311-52283BCE473EQ36983960-B8AB8681-E8C4-467E-824D-41A05225FA37Q37135262-3F9CB1F9-A64E-48BF-AD5A-B7E91FEBBA0DQ37160041-6957C2D3-33C6-4CA8-A296-088778175B17Q37206289-912F0F8E-BA7B-4D1B-9250-E19E8B49B43CQ37208769-983F886C-84FB-44A0-AC0B-B43BEF138EF0Q37241496-2DDE396F-B248-4478-AFC6-B7D64D6A77F4Q37338220-AA647DD1-EADB-461B-9438-5102C1658DC4Q37604076-AB721F68-7BF6-4D3D-A597-E0819F87F1F6Q37711674-9B23D468-D7D1-4307-90CD-151FF037873BQ37889274-97FB5C18-7F1B-4CB2-B5B0-A8B8A685CE2AQ37893534-1C26FE62-C37F-4C67-A0BA-3022A2EEA591Q38089837-499B799B-FB7A-431E-A101-C8E2CABAC66DQ38137829-593DF67B-1DC1-4D5B-89D2-B4B2CA026196Q38209464-F3725AAE-53CC-422C-B6D7-CEBB98B90602Q38314355-2B5338D7-425A-4DDF-9DCE-B3EA6F0E405D
P2860
Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Correlation between immunohist ...... st carcinomas from 37 centres.
@en
type
label
Correlation between immunohist ...... st carcinomas from 37 centres.
@en
prefLabel
Correlation between immunohist ...... st carcinomas from 37 centres.
@en
P2093
P356
P1476
Correlation between immunohist ...... ast carcinomas from 37 centres
@en
P2093
A D Watters
J Bartlett
P M Wencyk
P304
P356
10.1002/PATH.1313
P577
2003-04-01T00:00:00Z